Navigation Links
New head-to-head clinical studies reveal Reach Ultraclean toothbrush and floss deliver superior plaque removal compared to leading competitive products
Date:4/6/2009

MORRIS PLAINS, N.J., April 6, 2009 New head-to-head clinical trial results demonstrate that REACH ULTRACLEAN Toothbrush and Floss deliver superior plaque removal. The five studies conducted by Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc., and presented today during the 87th General Session and Exhibition of the International Association for Dental Research in Miami collectively found:

  • REACH ULTRACLEAN Floss removes up to two times more plaque than Glide* floss products. i
  • REACH ULTRACLEAN Toothbrush removes more plaque and provides improved gum health versus the Colgate 360** toothbrush. The REACH ULTRACLEAN Toothbrush also removes up to 90 percent of plaque in places that are hard to reach.ii

"The results of the clinical trials for the REACH ULTRACLEAN Toothbrush and Floss help set a new standard for the oral care tools patients use in the fight against plaque," said Sylvia Santos, RDH, MS, Associate Director, R&D, Johnson & Johnson Consumer & Personal Products Worldwide, Division of Johnson & Johnson Consumer Companies, Inc. "Through innovative design and unmatched cleaning technology, we continue to help patients achieve cleaner, healthier mouths."

About the Clinical Studies

Four randomized, observer-blind, three-way crossover and controlled studies were conducted for the REACH ULTRACLEAN Floss to determine dental plaque removal efficacy by flossing. The results demonstrate that REACH ULTRACLEAN Floss removes up to two times more interproximal plaque than Crest Glide Original Mint, Crest Glide Deep Clean, Crest Glide Whitening Plus Scope, Crest Glide Comfort Plus and Crest Glide Shred Guard. Subjects received a pre-flossing plaque examinationiii by a trained dental examiner and were randomly assigned to a sequence of treatments. Surrogate flossing was performed by a trained dental hygienist and post-flossing plaque assessments were conducted by the trained dental examiner. Subjects made three visits to the site with at least 24 hours of rest between each visit.

The fifth study, which examined the REACH ULTRACLEAN Toothbrush, was a 30-day observer-blind, parallel and controlled clinical study. It was conducted to determine dental plaque removal efficacy by brushing. Results show that the REACH ULTRACLEAN Toothbrush removes up to 90 percent of plaque in places that are hard to reach. The toothbrush also removes more plaque and provides improved gum health compared to Colgate 360 following 30 days of use. Subjects received assessments for safety, gingivitisiv and pre-brushing plaque levels on all teeth.v Subjects brushed in their usual manner for two minutes twice daily with their randomly assigned toothbrush and fluoride toothpaste. Subjects received pre- and post-brushing examinations for oral soft tissue assessment, gingivitis and plaque levels on Days 1 and 30.

About the Products

The REACH ULTRACLEAN Floss contains MICRO-GROOVES technology that flex to adapt to the contours between the teeth to provide superior cleaning. The exclusive MICRO-GROOVES technology slide easily to grab and remove plaque. The end result the unique, stretchy, no-shred dental floss offers a comfortable cleaning experience that is gentle on the gums.

The REACH ULTRACLEAN Toothbrush offers the signature REACH angled neck designed like a dental instrument to clean places that are hard to reach. Multi-level bristles and a dense cleansing tip together thoroughly clean between teeth, behind teeth and along the gum lines. The toothbrush also features an ergonomic handle with a thumb grip for greater control and comfort.


'/>"/>

Contact: Allison Goldstein
allison.goldstein@edelman.com
212-704-4511
Edelman Public Relations
Source:Eurekalert

Related medicine news :

1. Once-Weekly Exenatide Showed Statistical Superiority in Glucose Control Compared to BYETTA in Head-to-Head Study
2. Daiichi Sankyo, Lilly Announce New Prasugrel Head-to-Head Phase III Study Against Clopidogrel
3. In Landmark Phase III Head-to-Head Study, Prasugrel Statistically Superior to Clopidogrel in Reducing Risk of Heart Attack
4. Head-to-Head 96-Week Study Shows EPZICOM(R) is Comparable to Truvada(R) in Efficacy and Safety Measures in HIV Treatment-Naive Patients
5. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Clinical depression linked to abnormal emotional brain circuits
8. Preclinical study suggests organ-transplant drug may aid in lupus fight
9. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
10. Good Clinical Practice Journal Awards: Winners Announced
11. Microsoft Helps Developers of Clinical User Interfaces Improve Efficiency, Patient Safety With Free Toolkit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... 2017 , ... "TransFlare 4K Mystique comes with 44 colorful mysterious transitions that ... Christina Austin - CEO of Pixel Film Studios. , TransFlare 4K Mystique contains ... lens flare and light leak transitions have a very high-dynamic range for super smooth ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a ... has set out for each of his children. “The Angel” is the creation of ... Music in New York City, and impassioned writer. , When asked of her new ...
(Date:1/20/2017)... ... January 20, 2017 , ... D R Burton Healthcare Products ... was featured in a study indicating superior performance against competitive products in secretion ... Three Oscillating Positive Expiratory Pressure Devices During Simulated Breathing“ was published in the ...
(Date:1/20/2017)... ... 2017 , ... “Knowledge is God’s Lighthouse”: a moving and colorful collection ... is the creation of published author, Gene Gaapf, a retired truck driver, and a ... have been writing since high school and have many different titles,” Gaapf mentions about ...
(Date:1/19/2017)... ... 2017 , ... Today, the Centers for Medicare & Medicaid Services (CMS) announced ... Models (APMs) in 2017. Clinicians who participate in APMs are paid for the quality ... the Administration’s effort to build a system that delivers better care and one in ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis instruments and consumables for the medical ... to discuss its financial results for the third quarter ... will be at 4:15 p.m. ET on Thursday, January ... the third quarter fiscal year 2017 after the market ...
(Date:1/19/2017)... , Jan. 19, 2017  Sensus Healthcare, ... device company specializing in the treatment of non-melanoma ... keloids, with superficial radiation therapy, today announced that ... year 2016 financial results on Thursday, February 2, 2017 ... will hold a conference call with the investment ...
(Date:1/19/2017)... Shire plc (LSE: SHP, NASDAQ: ... and Drug Administration (FDA) has acknowledged receipt of the ... for SHP465, a long-acting, triple-bead, mixed amphetamine salts formulation. ... for Attention-Deficit/Hyperactivity Disorder (ADHD). The FDA is expected to ... the designated Prescription Drug User Fee Act (PDUFA) action ...
Breaking Medicine Technology: